Kyverna Therapeutics, Inc. (KYTX) Current Ratio
- Current ratio · latest quarter: Value 9.06×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 9.06× | Current assets / current liabilities. $206.54M ÷ $22.80M ≈ 9.06× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 206.54M USD | Assets, Current |
| Current obligations | 22.80M USD | Liabilities, Current |
| Cash and equivalents | 31.81M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 167.62M USD | Marketable Securities, Current |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 2.93M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $206.54M | $22.80M | $31.81M | $167.62M | (m) | (m) | $2.93M | (m) | 9.06× |
| 2026-03-31 | $241.73M | $29.67M | $32.19M | $204.25M | (m) | (m) | $11.60M | (m) | 8.15× |
| 2025-12-31 | $282.95M | $36.49M | $124.09M | $155.16M | (m) | (m) | $5.31M | (m) | 7.75× |
| 2025-09-30 | $174.93M | $33.87M | $34.16M | $136.97M | (m) | (m) | $3.02M | (m) | 5.16× |
| 2025-06-30 | $214.33M | $39.79M | $53.44M | $158.24M | (m) | (m) | $9.92M | (m) | 5.39× |
| 2025-03-31 | $247.65M | $33.29M | $56.87M | $185.78M | (m) | (m) | $8.47M | (m) | 7.44× |
| 2024-12-31 | $290.60M | $33.76M | $96.62M | $189.36M | (m) | (m) | $4.62M | (m) | 8.61× |
| 2024-09-30 | $325.37M | $30.98M | $104.66M | $216.92M | (m) | (m) | $9.93M | (m) | 10.50× |
| 2024-06-30 | $348.82M | $23.48M | $131.62M | $214.62M | (m) | (m) | $4.86M | (m) | 14.86× |
| 2024-03-31 | $375.49M | $21.86M | $224.29M | $145.51M | (m) | (m) | $7.45M | (m) | 17.17× |
| 2023-12-31 | $60.66M | $19.86M | $34.65M | $22.90M | (m) | (m) | $4.36M | (m) | 3.05× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |